Prognosis and Management of Advanced Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors (G3 NETs): A NET-CONNECT Study Performed in Four Expert Centers Abstract #2904

Introduction: G3 NETs are rare tumors with poorly defined prognosis and management.
Aim(s): Describe a retrospective cohort of patients with advanced digestive G3 NETs and depict their prognosis and treatment.
Materials and methods: Patients with advanced digestive G3 NET were included from 4 expert centers. Central pathological review was performed. Response rates (RR) to the two first treatment lines (primary endpoint) was analyzed depending on the type of treatment: neuroendocrine carcinoma (NEC)-like, alkylating agent (temozolomide or streptozotocin) (ALK), or somatostatin analogs (SSAs). Factors associated with RR and overall survival (OS) were assessed using logistic or Cox regression models, respectively.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Louis de Mestier

To read results and conclusion, please login ...

Further abstracts you may be interested in

#3044 Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)
Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Louis de Mestier
#2822 Outcome of Systemic Therapy in Secondary High-Grade Pancreatic Neuroendocrine Tumors
Introduction: Platinum-based chemotherapy has been the recommended treatment for metastatic high-grade pancreatic neuroendocrine neoplasms (panNEN). This strategy has been questioned for pancreatic neuroendocrine tumor grade 3 (panNET G3). The most optimal treatment strategy for low/intermediate grade panNETs that show progression to a high grade (secondary panNET G3) is unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD Kazhan Mollazadegan
#2875 Immunotherapy as Second-line Treatment in Grade 3 Neuroendocrine Carcinomas: A Prospective Case Series from an ENETS Center of Excellence
Introduction: Metastatic WHO grade 3 extra-pulmonary neuroendocrine carcinomas (EP-NEC) have a poor prognosis and optimal treatment after first-line platinum-etoposide chemotherapy remains unclear. A recent, small phase II study combining ipilimumab and nivolumab showed promising results
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Timon Vandamme
Keywords: NEC, immunotherapy
#3080 Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)
Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. med. Leonidas Apostolidis